Patents by Inventor Nathan E. Genung

Nathan E. Genung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WRN inhibitors
    Patent number: 12528806
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Grant
    Filed: January 27, 2025
    Date of Patent: January 20, 2026
    Assignee: Nimbus Wadjet, Inc.
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • TRICYCLIC FUSED WRN INHIBITORS
    Publication number: 20250368646
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: May 28, 2025
    Publication date: December 4, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN inhibitors
    Patent number: 12421233
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Grant
    Filed: January 27, 2025
    Date of Patent: September 23, 2025
    Assignee: Nimbus Wadjet, Inc.
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN inhibitors
    Patent number: 12344609
    Abstract: The present disclosure is directed to compounds of Formula II-e: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Grant
    Filed: January 27, 2025
    Date of Patent: July 1, 2025
    Assignee: Nimbus Wadjet, Inc.
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN INHIBITORS
    Publication number: 20250206738
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: December 20, 2024
    Publication date: June 26, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN INHIBITORS
    Publication number: 20250171441
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: January 27, 2025
    Publication date: May 29, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN INHIBITORS
    Publication number: 20250171440
    Abstract: The present disclosure is directed to compounds of Formula II-e: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: January 27, 2025
    Publication date: May 29, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN INHIBITORS
    Publication number: 20250171442
    Abstract: The present disclosure is directed to compounds of Formula I. and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: January 27, 2025
    Publication date: May 29, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • TRIAZOLO WRN INHIBITORS
    Publication number: 20250129069
    Abstract: The present disclosure is directed to triazolo based compounds, including compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: July 8, 2024
    Publication date: April 24, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov
  • WRN INHIBITORS
    Publication number: 20250034136
    Abstract: The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.
    Type: Application
    Filed: June 10, 2024
    Publication date: January 30, 2025
    Inventors: Derun Li, Angela V. West, Justin Caravella, Nathan E. Genung, Florian Bartels, Robert Lee Dow, Silvana Marcel Leit de Moradei, Nikolay Sitnikov